BioNTech to Report Third Quarter 2019 Financial Results and Operational Progress on November 14, 2019
November 07 2019 - 5:00AM
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a
clinical-stage biotechnology company focused on patient-specific
immunotherapies for the treatment of cancer and other serious
diseases, will announce on Thursday, November 14th, 2019 its
financial results for the third quarter ended September 30, 2019.
BioNTech will also host a conference call and webcast on the same
day at 08:00 a.m. ET (2:00 p.m. CET) to report its financial
results for the third quarter ended September 30, 2019 and provide
a corporate update.
To participate in the conference call, please
dial the following numbers five minutes prior to the start of the
call and provide the Conference ID: 8453733.
United States international: |
+1 631 510 7495 |
United States domestic (toll-free): |
+1 866 966 1396 |
Germany: |
+49 692 443 7351 |
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page of the Investor Relations section of the Company’s website at
https://biontech.de/. A replay of the webcast will be available
shortly after the conclusion of the call and archived on the
Company’s website for 30 days following the call.
About BioNTech
BioNTech was founded in 2008 on the
understanding that every cancer patient’s tumor is unique and
therefore each patient’s treatment should be individualized. Its
cutting-edge pipeline includes individualized mRNA-based product
candidates, innovative chimeric antigen receptor T cells, novel
checkpoint immunomodulators, targeted cancer antibodies and small
molecules. BioNTech has established relationships with seven
pharmaceutical collaborators, including Eli Lilly and Company,
Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the
Roche Group, Genevant and Pfizer, and has published over 150
peer-reviewed publications on its scientific approach.
For more information, please
contact:
BioNTech
SE
Michael Boehler, MD, Head of Global External
CommunicationsTel: +49 (0)6131 9084 1640Email:
Michael.Boehler@biontech.de
For all media inquiries:
Trophic Communications Gretchen Schweitzer /
Stephanie May, PhD Tel: +49 (0)89 23 88 77 30 or +49 171 185 56
82Email: May@trophic.eu
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024